Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Annals of Surgical Oncology
Journal
Overview
Identity
Overview
Publication Venue For
Race and Gender Disparities in Access to Parathyroidectomy: A Need to Change Processes for Diagnosis and Referral to Surgeons
. 28:476-483.
2021
The Impact of Residential Segregation on Pancreatic Cancer Diagnosis, Treatment, and Mortality
2020
Effect of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Malignancy Rates in Thyroid Nodules: How to Counsel Patients on Extent of Surgery
. 26:93-97.
2019
Select Choices in Benign Breast Disease: An Initiative of the American Society of Breast Surgeons for the American Board of Internal Medicine Choosing Wisely
®
Campaign
. 25:2795-2800.
2018
STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro
. 25:792-800.
2018
Benchmarking the American Society of Breast Surgeon Member Performance for More Than a Million Quality Measure-Patient Encounters
. 25:501-511.
2018
Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy
. 24:3674-3682.
2017
Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials
. 24:2855-2862.
2017
Optimizing Outpatient Pain Management After Thyroid and Parathyroid Surgery: A Two-Institution Experience
. 24:1951-1957.
2017
Breast Malignancies in Children: Presentation, Management, and Survival
. 24:1482-1491.
2017
Intraoperative Parathyroid Hormone Levels at 5 min Can Identify Multigland Disease
. 24:733-738.
2017
Measures of Appropriateness and Value for Breast Surgeons and Their Patients: The American Society of Breast Surgeons Choosing Wisely
®
Initiative
. 23:3112-3118.
2016
Antiplatelet and Anticoagulant Medications Significantly Increase the Risk of Postoperative Hematoma: Review of over 4500 Thyroid and Parathyroid Procedures
. 23:2874-2882.
2016
Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy
. 23:2715-2722.
2016
Compromised Outcome of Papillary Thyroid Cancer at Low-Volume Treatment Centers: Practice Makes Perfect?
. 23:355-357.
2016
[
99m
Tc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial
. 22:3708-3715.
2015
Clinical and Socioeconomic Factors Influence Treatment Decisions in Graves’ Disease
. 22:1196-1199.
2015
Outcomes After Subtotal Parathyroidectomy for Primary Hyperparathyroidism due to Hyperplasia: Significance of Whole vs. Partial Gland Remnant
. 22:966-971.
2015
All Thyroid Ultrasound Evaluations are Not Equal: Sonographers Specialized in Thyroid Cancer Correctly Label Clinical N0 Disease in Well Differentiated Thyroid Cancer
. 22:422-428.
2015
CaPTHUS Scoring Model in Primary Hyperparathyroidism: Can It Eliminate the Need for ioPTH Testing?
. 22:1191-1195.
2015
Chasing Calcitonin: Reoperations for Medullary Thyroid Carcinoma
. 22:7-8.
2015
Justified Follow-Up: A Final Intraoperative Parathyroid Hormone (ioPTH) Over 40 pg/mL is Associated with an Increased Risk of Persistence and Recurrence in Primary Hyperparathyroidism
. 22:454-459.
2015
Lymph Node Metastases do not Impact Survival in Follicular Variant Papillary Thyroid Cancer
. 22:158-163.
2015
Preventing Postoperative Hypocalcemia in Patients with Graves Disease: A Prospective Study
. 22:952-958.
2015
Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Secondary Analysis of TBCRC 017
. 22:75-81.
2015
The Use of Modified Four-Dimensional Computed Tomography in Patients with Primary Hyperparathyroidism: An Argument for the Abandonment of Routine Sestamibi Single-Positron Emission Computed Tomography (SPECT)
. 22:139-145.
2015
Erratum to: Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival (Annals of Surgical Oncology, DOI: 10.1245/S10434-014-3486-Z)
. 21:1538.
2014
Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma
. 21:449-457.
2014
Assessment of Erlotinib as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer Patients
. 21:4263-4269.
2014
Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival
. 21:1530-1537.
2014
Failure of Radioactive Iodine in the Treatment of Hyperthyroidism
. 21:4174-4180.
2014
Hesperetin Activates the Notch1 Signaling Cascade, Causes Apoptosis, and Induces Cellular Differentiation in Anaplastic Thyroid Cancer
. 21:497-504.
2014
Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657)
. 21:2889-2896.
2014
Posterior 'superior mesenteric artery first' approach for resection of locally advanced pancreatic cancer
. 21:1927-1928.
2014
Radioactive iodine remnant uptake after completion thyroidectomy: Not such a complete cancer operation
. 21:1379-1383.
2014
Silencing of UCHL1 by CpG Promoter Hyper-methylation is Associated with Metastatic Gastroenteropancreatic Well-Differentiated Neuroendocrine (Carcinoid) Tumors
. 21:672-679.
2014
Surgeon and Staff Radiation Exposure During Radioguided Parathyroidectomy at a High-Volume Institution
. 21:3853-3858.
2014
Thyroidectomy as primary treatment optimizes body mass index in patients with hyperthyroidism
. 21:2303-2309.
2014
MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through akt inhibition
. 20:3862-3868.
2013
Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma
. 20:3059-3065.
2013
Minimal benefit to subsequent intraoperative parathyroid hormone testing after all four glands have been identified
. 20:4200-4204.
2013
Multigland disease and slower decline in intraoperative PTH characterize mild primary hyperparathyroidism
. 20:4205-4211.
2013
Presentation, management, and outcomes of hyperparathyroidism in octogenarians and nonagenarians
. 20:4195-4199.
2013
Comparative evaluation of [
99m
Tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: Results of two phase 3 trials
. 20:2590-2599.
2013
Parathyroid cryopreservation after parathyroidectomy: A worthwhile practice?
. 20:2256-2260.
2013
Disparities in pancreas cancer care
. 20:2078-2087.
2013
Impact of lymph node ratio on survival in papillary thyroid cancer
. 20:1906-1911.
2013
Doing away with the rule of 10 %
. 20:1403-1404.
2013
Hereditary medullary thyroid cancer: Age-appropriate thyroidectomy improves disease-free survival
. 20:1451-1455.
2013
Diversity of stage III melanoma in the era of sentinel lymph node biopsy
. 20:956-963.
2013
Utility of
111
indium-pentetreotide scintigraphy in patients with neuroendocrine tumors
. 20:640-645.
2013
Sestamibi imaging for primary hyperparathyroidism: The impact of surgeon interpretation and radiologist volume
. 19:3827-3831.
2012
Surveillance of small rectal carcinoid tumors in the absence of metastatic disease
. 19:3486-3490.
2012
The role of gender in primary hyperparathyroidism: Same disease, different presentation
. 19:2958-2962.
2012
Sestamibi-negative patients: To operate or image?
. 19:2086-2087.
2012
Does the final intraoperative PTH level really have to fall into the normal range to signify cure?
. 19:1862-1867.
2012
Adverse effects of smoking on postoperative outcomes in cancer patients
. 19:1430-1438.
2012
Is focused minimally invasive parathyroidectomy appropriate for patients with familial primary hyperparathyroidism?
. 19:1264-1268.
2012
Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma
. 19:973-980.
2012
Presurgical localization of parathyroid adenomas with magnetic resonance imaging at 3.0 T: An adjunct method to supplement traditional imaging
. 19:981-989.
2012
Limitations of the ACS NSQIP in thyroid surgery
. 18:3529-3530.
2011
Does previous head and neck irradiation increase the chance of multigland disease in patients with hyperparathyroidism?
. 18:2240-2244.
2011
Inadequate cytology of thyroid nodules. Repeat it or live with it
. 18:1222-1223.
2011
Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer
. 18:1506-1511.
2011
A comparison of the ligasure and harmonic scalpel in thyroid surgery: A single institution review
. 18:214-218.
2011
Guideline recommended gastric cancer care in the elderly: Insights into the applicability of cancer trials to real world
. 18:26-33.
2011
What is the added benefit of cervical ultrasound to
99m
Tc- sestamibi scanning in primary hyperparathyroidism?
. 18:2907-2911.
2011
25-Hydroxyvitamin D status does not affect intraoperative parathyroid hormone dynamics in patients with primary hyperparathyroidism
. 17:2958-2962.
2010
Minimal disease in the sentinel lymph node: How to best measure sentinel node micrometastases to predict risk of additional non-sentinel lymph node disease
. 17:2909-2919.
2010
Extremity soft tissue sarcoma care in the elderly: Insights into the generalizability of NCI cancer trials
. 17:1732-1738.
2010
Body mass index does not affect postoperative morbidity and oncologic outcomes of total mesorectal excision for rectal adenocarcinoma
. 17:1606-1613.
2010
Factors associated with false-negative sentinel lymph node biopsy in melanoma patients
. 17:709-717.
2010
Utility of intraoperative PTH for primary hyperparathyroidism due to multigland disease
. 16:3450-3454.
2009
Papillary thyroid microcarcinomas: Big decisions for a small tumor
. 16:3132-3139.
2009
Inhibition of phosphatidylinositol 3-kinase/akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors
. 16:2936-2942.
2009
Disparities in gastric cancer outcomes among Asian ethnicities in the USA
. 16:2433-2441.
2009
Combination therapy with histone deacetylase inhibitors and lithium chloride: A novel treatment for carcinoid tumors
. 16:481-486.
2009
Older age and larger tumor size predict malignancy in Hürthle cell neoplasms of the thyroid
. 15:2842-2846.
2008
Suberoyl bishydroxamic acid activates Notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma
. 15:2600-2605.
2008
The influence of surgical approach on quality of life after parathyroid surgery
. 15:1559-1565.
2008
The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma
. 15:900-905.
2008
Author reply [2]
. 15:380-381.
2008
Isolated adrenal mass in patients with a history of cancer: Remember pheochromocytoma
. 14:2358-2362.
2007
The negative sestamibi scan: Is a minimally invasive parathyroidectomy still possible?
. 14:2363-2366.
2007
Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response
. 14:2150-2158.
2007
Local/cervical block anesthesia versus general anesthesia for minimally invasive parathyroidectomy: What are the advantages?
. 14:744-749.
2007
Radioguided parathyroidectomy in patients with familial hyperparathyroidism
. 14:739-743.
2007
Characteristics and treatment of metaplastic breast cancer: Analysis of 892 cases from the national cancer data base
. 14:166-173.
2007
Is tumor size the best predictor of outcome for papillary thyroid cancer?
. 13:1524-1528.
2006
Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts
. 13:1145-1155.
2006
Fine-needle aspiration optimizes surgical management in patients with thyroid cancer
. 13:859-863.
2006
Trends in hospital and surgeon volume and operative mortality for cancer surgery
. 13:851-858.
2006
Long-term outcomes in patients with calciphylaxis from hyperparathyroidism
. 13:96-102.
2006
Are minimally invasive techniques for ablation of breast cancer ready for "prime time"?
. 11:115-116.
2004
The utility of frozen section evaluation for follicular thyroid lesions
. 11:94-98.
2004
Expression of p53 and proliferation index as prognostic factors in gastrointestinal sarcomas
. 10:190-195.
2003
Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma
. 10:839-851.
2003
Annals of surgical oncology impact factor/rating has dramatically increased.
. 10:1-3.
2003
The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined.
. 10:65-71.
2003
Long-term complications of breast-conservation therapy: Can the incidence be reduced?
. 9:524-525.
2002
Editorial commentary on scientific fraud
. 9:419-420.
2002
Palliative thyroidectomy for malignant lymphoma of the thyroid
. 9:907-911.
2002
Primary thyroid lymphoma: Can the diagnosis be made solely by fine-needle aspiration?
. 9:298-302.
2002
Utilization of sentinel lymph node mapping to determine pathologic outcomes for patients receiving neoadjuvant chemotherapy for locally advanced breast cancer
. 9:217-219.
2002
Sentinel node biopsy for cutaneous melanoma in the head and neck
. 8:716-719.
2001
Sentinel node biopsy for cutaneous melanoma in the head and neck.
. 8:716-719.
2001
Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas.
. 8:101-108.
2001
Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas
. 8:101-108.
2001
Multimodality treatment of merkel cell carcinoma: Case series and literature review of 1024 cases
. 8:204-208.
2001
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm)
. 7:87-97.
2000
Current status of endocrine therapy for advanced breast cancer
. 6.
1999
Future directions in endocrine treatment of advanced breast cancer
. 6.
1999
Role of new endocrine therapies in the treatment of advanced breast cancer: Introduction
. 6.
1999
Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer
. 6.
1999
Refining the optimal technical approach for sentinel node localization in breast cancer patients
. 6:418-419.
1999
Microstaging of sentinel lymph nodes
. 6:15-16.
1999
The 1999 James Ewing lecture: In pursuit of molecules of oncogenesis and neoplastic therapy
. 6:528-541.
1999
Molecular oncogene markers and their significance in cutaneous malignant melanoma
. 5:253-260.
1998
Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells
. 5:279-286.
1998
Indications for axillary dissection in T1 breast cancer
. 5:4-8.
1998
Role of axillary lymph node dissection after tumor downstaging
. 5:665-666.
1998
Optimal surgical treatment of invasive lobular carcinoma of the breast
. 4:545-550.
1997
The society at a crossroads: Milestones and imperatives for cancer clinical trials
. 4:523-539.
1997
Topographic genotyping of colorectal carcinoma: From a molecular carcinogenesis model to clinical relevance
. 4:269-278.
1997
Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial.
. 3:110-117.
1996
Local recurrence in malignant melanoma: Long-term results of the multiinstitutional randomized surgical trial
. 3:446-452.
1996
Malignant potential in intestinal juvenile polyposis syndromes
. 2:386-391.
1995
Insurance coverage of patients with breast cancer in the 1991 Commission on Cancer patient care evaluation study
. 1:462-467.
1994
What is a surgical oncologist?
. 1:2-4.
1994
Identity
International Standard Serial Number (issn)
1068-9265
Electronic International Standard Serial Number (eissn)
1534-4681